Join Growin Stock Community!

Celcuity inc.CELC.US Overview

US StockHealthcare
(No presentation for CELC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CELC AI Insights

CELC Overall Performance

CELC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CELC Recent Performance

-2.77%

Celcuity inc.

0.05%

Avg of Sector

-0.31%

S&P500

CELC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CELC Key Information

CELC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CELC Profile

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Price of CELC

CELC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CELC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
44.22
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
44.22
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CELC's latest earnings report released?

    The most recent financial report for Celcuity inc. (CELC) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CELC's short-term business performance and financial health. For the latest updates on CELC's earnings releases, visit this page regularly.

  • How much debt does CELC have?

    As of the end of the reporting period, Celcuity inc. (CELC) had total debt of 320.35M, with a debt ratio of 0.67. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CELC have?

    At the end of the period, Celcuity inc. (CELC) held Total Cash and Cash Equivalents of 74.25M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CELC go with three margins increasing?

    In the latest report, Celcuity inc. (CELC) did not achieve the “three margins increasing” benchmark, with a gross margin of 50%%, operating margin of -27,824.03%%, and net margin of -28,444.16%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CELC's profit trajectory and future growth potential.

  • Is CELC's EPS continuing to grow?

    According to the past four quarterly reports, Celcuity inc. (CELC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.92. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CELC?

    Celcuity inc. (CELC)'s Free Cash Flow (FCF) for the period is -44.91M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 117.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CELC?

    The latest valuation data shows Celcuity inc. (CELC) has a Price-To-Earnings (PE) ratio of -24.46 and a Price/Earnings-To-Growth (PEG) ratio of 1.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.